Key Highlights

  • Net income climbed 25.8% to USD 20.6 million in the third quarter of 2026, according to the November 3, 2026 release, up from USD 16.4 million a year earlier.
  • Net sales rose 11.6% to USD 172.4 million, with organic growth of 11.1%, and MedTech sales advanced 12.5% during the quarter.
  • GAAP diluted EPS reached USD 2.64 and adjusted diluted EPS USD 2.88, versus USD 2.11 and USD 2.39 in the third quarter of 2025.
  • Gross Margin expanded to 29.4% from 27.7%, while SG&A grew 21.4% to USD 23.2 million, equal to 13.4% of sales.

Profit Growth Outpaces Sales in the Third Quarter

UFP Technologies (NASDAQ:UFPT) is a contract development and Manufacturing organization serving medical devices, sterile packaging and other engineered products, and it reported results for the quarter ended September 30, 2026 on November 3, 2026. Net sales increased 11.6% to USD 172.4 million, Operating Income climbed 18.1% to USD 27.6 million, and Net Income rose 25.8% to USD 20.6 million. Adjusted operating income grew 14.5% to USD 30.1 million, and adjusted EBITDA advanced 15.3% to USD 35.4 million. Across nine months, sales hit USD 500.6 million, up 10.3%, and net income reached USD 59.0 million, up 16.2%, with Organic Sales growth of 7.9%. By simple subtraction, the gap between that organic figure and the 10.3% total growth reflects contributions from outside organic sales.

Gross Margin and Lower Interest Explain the Gap

Profit grew faster than sales for two visible reasons. Gross margin improved 1.7 points to 29.4%, and net interest expense dropped to USD 1.5 million from USD 2.4 million, a reduction of roughly USD 0.9 million by simple subtraction of the two reported figures. Long-term Debt including the current portion was USD 96.0 million on September 30, 2026, down from about USD 135.5 million at December 31, 2025, a difference also derived by simple arithmetic. Management attributed the margin to scaling new programs in the Dominican Republic and to gains in legacy operations. Selling, general and administrative expenses rose 21.4%, faster than sales, and adjusted SG&A climbed to 12.0% of sales from 10.7%. GAAP and adjusted Earnings differ by about USD 0.24 per share this quarter, and adjusted figures are non-GAAP.

Program Transfers Lag Plan, Customer Concentration and Credit Line Expansion

The company said scheduled program transfers to the Dominican Republic and margin improvement at AJR are still behind plan. Its risk disclosures flag reliance on its two largest customers, the possibility that Supply agreement volumes or rebates fall short, tariffs, a previous cyber incident, and the chance that a push to enlarge its credit Facility fails on favorable terms. Management is working to expand the facility to fund acquisitions and has added capacity at DAS Medical for double-digit growth in 2027. Cash was USD 20.6 million, while receivables and inventories both rose since December. A conference call was set for 8:30 a.m. ET on November 4, 2026.

Where Things Stand

Profit outpaced sales because gross margin widened and interest costs fell, though overhead rose faster than revenue. The 25.8% net income gain at UFP Technologies (NASDAQ:UFPT) rests on margin and financing effects alongside 11.6% sales growth, with MedTech up 12.5%. The quality of the beat depends on margins holding while Dominican Republic transfers catch up, on whether a larger credit facility can fund acquisitions, and on the two largest customers keeping volumes steady. The November 4 call should add detail on the 2027 growth plans management called optimistic, and the release extract reviewed contained no formal outlook.